Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
PLIANT THERAPEUTICS, INC. (PLRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs: "LEASE AGREEMENT",
"TERMINATION"
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results Initiation of Phase 2b BEACON-IPF trial of bexotegrast in patients with IPF"
08/03/2023 144 Form 144 - Report of proposed sale of securities:
07/20/2023 144 Form 144 - Report of proposed sale of securities:
06/08/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results"
05/01/2023 8-K Quarterly results
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/27/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
03/20/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
03/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/09/2023 10-K Annual Report for the period ended December 31, 2022
03/09/2023 8-K Quarterly results
Docs: "Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results"
03/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/23/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
02/14/2023 SC 13G/A Third Rock Ventures III, L.P. reports a 4.4% stake in Pliant Therapeutics, Inc.
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A FMR LLC reports a 9% stake in PLIANT THERAPEUTICS INC
01/25/2023 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement, by and among Pliant Therapeutics, Inc. and J.P. Morgan Securities LLC and Piper Sandler & Co., as representatives of the several underwriters named therein",
"Opinion of Sidley Austin LLP"
01/25/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
01/24/2023 S-3MEF Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)]:
01/23/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
01/23/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
01/23/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis"
01/09/2023 8-K Quarterly results
11/18/2022 8-K Quarterly results
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
09/16/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Bylaws, as further amended and restated on September 14, 2022",
"Bylaws, as further amended and restated on September 14, 2022"
08/31/2022 SC 13G/A Novartis Institutes for BioMedical Research, Inc. reports a 4.4% stake in Pliant Therapeutics, Inc.
08/10/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy